It’s time to let the FDA know that eczema is more than skin deep

Announcing the first patient-focused drug development meeting dedicated to eczema. September 23, 2019
NEA News

By Kathryn Jones

Published On: Aug 1, 2019

Last Updated On: Aug 25, 2020

Developing safe and effective treatments for people with eczema are at the core of a special initiative called “More Than Skin Deep” launched on July 31, 2019.

The National Eczema Association has partnered with four nonprofit organizations to create a series of opportunities to inform and shape development of drugs and medical devices designed to treat eczema – and we can’t do it without you!

We will jointly hold a patient-focused drug development (PFDD) meeting on Sept. 23, 2019, in the Washington, D.C., area.

This important meeting will help U.S. Food and Drug Administration (FDA) staff and clinical trial sponsors better understand the struggles of living with eczema, what patients and caregivers value most in terms of treatment benefits, and what risks and side effects they are willing to tolerate.

“For far too long, adults and children have struggled with the itch, pain and other physical symptoms of eczema while also coping with the emotional toll and psychosocial effects of this disease,” said NEA CEO Julie Block.

“This is a once-in-a-lifetime opportunity to come together as a community, unhide and share our lived experiences with key decision-makers and have a lasting impact on the eczema treatments of tomorrow. We have an important audience ready to listen, and now it’s time to make our voices heard.”

Be part of this landmark initiative! Visit More Than Skin Deep to learn how YOU can get involved by participating in the meeting (in person or by webcast) and responding to a new survey.

Get the latest eczema news delivered to your inbox.

NEA Newsletter Signup

Get the latest eczema news delivered to your inbox.
  • This field is for validation purposes and should be left unchanged.